Hydroxypropyl beta cyclodextrin adjuvanted influenza split vaccine - Kitasato Daiichi Sankyo Vaccine

Drug Profile

Hydroxypropyl beta cyclodextrin adjuvanted influenza split vaccine - Kitasato Daiichi Sankyo Vaccine

Alternative Names: HP-beta-CyD-adjuvanted influenza split vaccine

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kitasato Daiichi Sankyo Vaccine
  • Class Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 30 Nov 2017 Kitasato Daiichi Sankyo Vaccine has been acquired by Daiichi Sankyo Company
  • 08 Sep 2017 Preclinical trials in Influenza virus infections in Japan before September 2017 (SC)
  • 08 Sep 2017 Kitasato-Daiichi Sankyo Vaccine plans a phase I trial for Influenza virus infections (Prevention) in Japan (UMIN000028530)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top